Last reviewed · How we verify
Recombinant Fowlpox-GM-CSF — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Recombinant Fowlpox-GM-CSF (Recombinant Fowlpox-GM-CSF) — National Cancer Institute (NCI).
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Recombinant Fowlpox-GM-CSF TARGET | Recombinant Fowlpox-GM-CSF | National Cancer Institute (NCI) | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Recombinant Fowlpox-GM-CSF CI watch — RSS
- Recombinant Fowlpox-GM-CSF CI watch — Atom
- Recombinant Fowlpox-GM-CSF CI watch — JSON
- Recombinant Fowlpox-GM-CSF alone — RSS
Cite this brief
Drug Landscape (2026). Recombinant Fowlpox-GM-CSF — Competitive Intelligence Brief. https://druglandscape.com/ci/recombinant-fowlpox-gm-csf. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab